Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS
Our Communication Services
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two key voices driving the PRIME-ROSE initiative: Gro Live Fagereng, Project Manager of the EU-project PRIME-ROSE and Coordinator of Precision Cancer Medicine at Oslo University Hospital, and Henk van der Pol, Ph.D. Candidate at Leiden University Medical Center. They explain the DRUP (Drug Rediscovery Protocol) trial approach, which repurposes existing oncology drugs for new off-label uses, and discuss how this can widen treatment options for patients with rare or underserved tumor types. They also describe the complexities of consolidating small patient cohorts across multiple sites and countries, shedding light on how data models like OMOP help standardize clinical information.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
TEMPEST mHealth : mHealth in 28 EU Member States
3rd November, 2014
By Wendy L. Currie and Jonathan J.M. Seddon
One of the biggest health care challenges in the coming years is how technology can be used to improve health service delivery. With the steadily increasing average life expectancy across all of Europe expected to be over 80 by 2025 and 82.5 by 2050, new and improved processes need to be delivered to meet future health requirements.
Database Exploitation Could Slash Clinical Trial Durations, Cut Costs
29th October, 2014
A presentation by health care consultancy VitalTransformation shows that a fifth could be cut off clinical trial times and up to $300 million saved if databases were used for trial recruitment.
Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law
19th May, 2014
Abstract
Eroom’s Law is, literally, Moore’s law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, “the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms”. Pharmaceutical companies have invested enormous sums in new molecular entities (NME) in the areas of unmet medical need identified by the World Health Organization (WHO), but the approval rates from phase I are only 7% for cardiovascular disease, dropping to 4% for Alzheimer’s disease.
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
 |
 |
|---|---|
 |
 |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
VT on X
The Inflation Reduction Act's Impact upon Early-stage Venture Capital Investments
— Duane Schulthess (@DuaneSchulthess) January 8, 2025
-Aggregate small molecule investments declined by 70%
-Individual small molecule investments decline in size by -50% as exposure to Medicare increases (p < 0.0018).https://t.co/JMfjrToyxe
New study "The EU General Pharmaceutical Legislation & Clawbacks: Calculated impacts – both designed and unintended." https://t.co/issED0DnUn@amgen @AbbVie @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform @abbvieuk
— VitalTransformation (@VitalTransform) April 18, 2024
Our clients include many of the world’s leading health care organisations.
